Histogenics has a new face in the corner office with the appointment of Peter Greenleaf, an AstraZeneca veteran favored by the board for his experience moving products toward commercialization.
The company has its eyes on an end-stage pivotal trial for NeoCart, a device that uses patients’ own cells to regenerate knee cartilage.